Trial · NCT07904065
Two Bovine Xenografts in Lateral Window Sinus Augmentation With or Without Bone Marrow Blood
NCT07904065, Not applicable, Recruiting, Universidad del Desarrollo
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Two Bovine Xenografts in Lateral Window Sinus Augmentation With or Without Bone Marrow Blood. Trials, record NCT07904065. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07904065
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Two Bovine Xenografts in Lateral Window Sinus Augmentation With or Without Bone Marrow Blood
- NCT number
- NCT07904065
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Universidad del Desarrollo
- Conditions
- Alveolar Bone Loss, Sinus Floor Augmentation, Edentulous Alveolar Ridge
- Interventions
- Deproteinized Bovine Bone Mineral (Bio-Oss), Deproteinized Bovine Bone Mineral (InterOss), Mandibular Bone Marrow Blood Aspiration
- First posted
- 2026-10-29
- Last updated
- 2026-10-29
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percentage of New Vital Bone in the Augmented Sinus | 8 months after sinus augmentation | Proportion of the total area of the bone core biopsy occupied by newly formed vital bone (%NB = vital bone area / total sample area x 100), measured by histomorphometry on the two most central hematoxylin-eosin stained sections of a trephine core (2.3 mm inner diameter, approximately 7 mm long) harvested from the grafted area at implant placement. Analysis is performed under light microscopy by a pathologist blinded to group allocation. |
| Secondary | Percentage of Residual Graft Particles | 8 months after sinus augmentation | Proportion of the total biopsy area occupied by residual xenograft particles (%GP), measured by histomorphometry on hematoxylin-eosin stained sections of the bone core harvested at implant placement, by a pathologist blinded to group allocation. |
| Secondary | Percentage of Connective Tissue | 8 months after sinus augmentation | Proportion of the total biopsy area occupied by connective/fibrovascular tissue (%CT), measured by histomorphometry on hematoxylin-eosin stained sections of the bone core harvested at implant placement, by a pathologist blinded to group allocation. |
| Secondary | Percentage of Total Bone | 8 months after sinus augmentation | Proportion of the total biopsy area occupied by vital bone plus residual graft particles (%TB), measured by histomorphometry on hematoxylin-eosin stained sections of the bone core harvested at implant placement, by a pathologist blinded to group allocation. |
| Secondary | Radiographic Bone Height Gain (Sagittal View) | Baseline (preoperative) and 8 months after sinus augmentation | Difference between augmented bone height (ARRSI) and residual alveolar ridge height (ARRS), in millimeters, measured on sagittal CBCT slices with BlueSky Plan software. Each value is the mean of three slices 1 mm apart. Measurements are performed by a calibrated examiner blinded to group allocation. |
| Secondary | Radiographic Bone Height Gain (Coronal View) | Baseline (preoperative) and 8 months after sinus augmentation | Difference between augmented bone height (ARRCI) and residual alveolar ridge height (ARRC), in millimeters, measured on coronal CBCT slices with BlueSky Plan software. Each value is the mean of three slices 1 mm apart. Measurements are performed by a calibrated examiner blinded to group allocation. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07904065
GET https://conductscience.org/api/trials/v1/NCT07904065/registered